The convenience gap is closing. Amgen competitors noticed.

The convenience gap is closing. Amgen's competitors noticed.

Amgen reported positive Phase 3 results on April 6 for a subcutaneous formulation of Tepezza, its blockbuster thyroid eye disease drug — data that directly addresses the main competitive vulnerability of the existing IV version. In the trial, 76.7% of patients showed a proptosis response at week 24, compared to 19.6% in the placebo arm (p<0.0001). Mean proptosis reduction was 3.17 millimeters versus 0.80 millimeters for placebo. The drug was delivered via an automated on-body injector designed for at-home or clinic use, and no new safety signals emerged.

Tepezza is the cornerstone of Amgen's rare disease portfolio. Amgen acquired it as part of the $27.8 billion Horizon Therapeutics deal in 2023 — one of the largest biotech acquisitions in history — betting that the drug's rare disease positioning and pricing power would justify the premium. The IV formulation requires patients to spend hours at an infusion center, which has been the opening that smaller competitors are racing to exploit.

That opening is now narrower. Viridian Therapeutics has veligrotug with a BLA already submitted after completing Phase 3, and a second candidate, VRDN-003, actively in Phase 3. Sling Therapeutics is advancing an oral IGF-1R inhibitor in a Phase 2b/3 study. Both are built around the same pitch: an at-home pill or injection would be more convenient than a hours-long IV session. If subcutaneous Tepezza converts to approval with these results, that pitch gets significantly harder.

The cross-trial comparisons are real but limited. These competitors have not run head-to-head studies against Tepezza, and the Phase 3 populations differ enough that direct efficacy comparisons are unreliable. What is clear is that subcutaneous Tepezza preserved the clinical profile of the IV version — the efficacy numbers are in the same ballpark, and no new safety signals appeared over 24 weeks. The FDA will make the approval decision, and the timeline is not yet public.

The competitive threat is not theoretical. Viridian's veligrotug BLA is already under FDA review, and Sling is running a Phase 2b/3 study — which means Amgen's window to establish subcutaneous Tepezza as the standard of care is measured in the time the agency takes to review Viridian's application and rule on Sling's trial. The data Amgen just reported buys that window. Whether it closes it entirely depends on what the FDA says.

The infusion center was always the vulnerability. Amgen just addressed it.